EP1356026A2 - Codage de genes de micromonospora echinospora pour la biosynthese de la calicheamicine, et autoresistance vis-a-vis de cette substance - Google Patents

Codage de genes de micromonospora echinospora pour la biosynthese de la calicheamicine, et autoresistance vis-a-vis de cette substance

Info

Publication number
EP1356026A2
EP1356026A2 EP01274067A EP01274067A EP1356026A2 EP 1356026 A2 EP1356026 A2 EP 1356026A2 EP 01274067 A EP01274067 A EP 01274067A EP 01274067 A EP01274067 A EP 01274067A EP 1356026 A2 EP1356026 A2 EP 1356026A2
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
acid molecule
calicheamicin
orβ
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01274067A
Other languages
German (de)
English (en)
Inventor
Jon Thorson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/724,797 external-priority patent/US6733998B1/en
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of EP1356026A2 publication Critical patent/EP1356026A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/64—Preparation of S-glycosides, e.g. lincomycin

Definitions

  • the present invention relates to a biosynthetic gene cluster of Micromonospora echinospora spp. calichensis.
  • the calicheamicin biosynthetic gene cluster contains genes encoding for proteins and enzymes used in the biosynthetic pathway and construction of calicheamicin' s aryltetrasaccharide and aglycone, and the gene conferring calicheamicin resistance.
  • the present invention also relates to isolated genes of the biosynthetic cluster and their corresponding proteins.
  • the invention relates to DNA hybridizing with the calicheamicin gene cluster and the isolated genes of that cluster.
  • the invention also relates to expression vectors containing the biosynthetic gene cluster, the individual genes, or functional variants thereof.
  • the members of the first category of enediynes are classified as chromoprotein enediynes because they possess a novel 9-membered ring chromophore core structure, which also requires a specific associated protein for chromophore stabilization.
  • the members of the second category of enediyne are classified as non-chromoprotein enediynes. These enediynes contain a 10-membered ring, which requires no additional stabilization factors.
  • warhead This enediyne ring structure is often referred to as the "warhead.”
  • the warhead induces DNA damage, which is frequently a double-stranded cleavage and appears to be irreparable. This type of DNA damage is usually nonrepairable for the cell and is most often lethal. Because of these remarkable chemical and biological properties, there has been an intense effort by both the pharmaceutical industry and academia to study these substances with the goal of developing new and clinically useful therapeutic anti-tumor agents.
  • the 9-membered ring chromoprotein enediyne subfamily is comprised of: neocarzinostatin from Streptomyces carzinostaticus, (Myers, A.G., et al., J Am. Chem. Soc, 110, 7212-7214 (1988)); kedarcidin from Actinomycete 585-6, (Leet, J.E., et al., J. Am. Chem. Soc, 114, 7946-7948 (1992)), N1999A2 from Streptomyces globisporus, (Yoshida, K., et al.
  • a required apoprotein acts as a stabilizer and specific carrier for the unstable chromophore, and for its transport and interaction with target DNA.
  • the non-chromophore enediyne subfamily is comprised of calicheamicin from Micromonospora echinospora spp. calichensis; namenamicin from Polysyncraton lithostrotum; esperamicin from Actinomadura verrucosospora; and dynemicin from Micromonospora chersina.
  • Enediyne antibiotics have potential as anticancer agents because of their ability to cleave DNA; however, many of these compounds are too toxic to be used currently in clinical studies.
  • Today, only calicheamicin is known to be currently used in clinical trials; and it has provided promising results as an anticancer agent.
  • MyloTargTM a calicheamicin-antibody conjugate also known as CMA-676 was approved by the FDA in January of 2000 to treat acute myelogenous leukemia.
  • the enediynes also potentially have utility as anti-infective agents, provided that toxicity can be managed.
  • Calicheamicin has two distinct structural regions: the aryltetrasaccharide and the aglycone (also known as the warhead).
  • the aryltetrasaccharide displays a highly unusual series of glycosidic, thioester, and hydroxylamine linkages and serves to deliver the drug primarily to specific tracts (5'-TCCT-3' and 5'-TTTT-3') within the minor groove of DNA when those sequences are available.
  • specificity is also context-dependent.
  • the aglycone of calicheamicin consists of a highly functionalized bicyclo[7.3.1]tridecadiynene core structure with an allylic trisulfide serving as the triggering mechanism.
  • calicheamicin This activity of calicheamicin has sparked considerable interest in the pharmaceutical industry culminating in the recent FDA approval of the calicheamicin- antibody conjugate MyloTargTM (CMA-676) to treat acute myelogenous leukemia (AML). Additionally, similar strategies have been used in phase I trials to treat breast cancer. A massive program to examine calicheamicin conjugated to alternative delivery systems has also recently been undertaken. Hamann, P.R., et al., 87th Annual Meeting of the American Association of Cancer Research, Washington, D.C., pp. 471 (1996); Hinman, L.M., et al., Cancer Res., 53, 3336 (1993); Hinman, L.
  • calicheamicin The biological activity and molecular architecture of calicheamicin has also prompted a search for potentially useful analogs.
  • one group has produced a novel calicheamicin ⁇ shown to effectively suppress growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma.
  • random mutagenesis of M. echinospora and screening for mutant strains with improved biosynthetic potential has also been pursued.
  • Rothstein D. M., Enediyne Antibiotics as Antitumor Agents, pp. 107-126 (1995).
  • the toxicity of the enediyne compounds, including calicheamicin, centers on the problem of directing the compound to the cleave only the DNA ofinterest, such as tumor cell DNA, and not the DNA of the host. Due to calicheamicin' s powerful ability to cleave DNA, scientists have investigated the mechanism by which calicheamicin-producing organism protects itself against the DNA-cleaving activity of the molecule. Rothstein, D. M., Enediyne Antibiotics as Antitumor Agents, p. 77 (1995). Prior to this invention, knowledge of genes encoding for non-chromoprotein enediyne self resistance was completely lacking.
  • the present invention relates to the first identification, isolation, and cloning of a nonchromoprotein enediyne biosynthetic gene cluster and mapping and nucleotide sequence analysis of the genes within the cluster.
  • the invention provides the entire calicheamicin-biosynthetic cluster and biochemical studies of aryltetrasaccharide biosynthesis. Furthermore, the calicheamicin self-resistance gene and protein have been isolated, as have the genes and resulting enzymes for steps within the calicheamicin cascade.
  • the invention also provides for construction of enediyne overproducing strains, for rational biosynthetic modification of bioactive secondary metabolites, for new drug leads, and for an enediyne combinatorial biosynthesis program.
  • the present invention provides an isolated nucleic acid molecule from a nonchromoprotein enediyne biosynthetic gene cluster from Micromonospora echinospora comprising said nucleic acid molecule, a portion or portions of said nucleic acid molecule wherein said portion or portions encode a protein, a portion or portions of said nucleic acid molecule wherein said portion or portions encode a biologically active fragment of a protein.
  • the isolated nucleic acid molecule may be single- or double-stranded.
  • nucleic acid molecule, polypeptide, or protein described as being "from” e.g., an organism or gene cluster may have been isolated from such organism or gene cluster; alternatively, it may be a molecule which has been produced using synthetic, chemical, recombinant, or other such methods and comprise an amino acid or nucleotide sequence which may be isolated from such organism or gene cluster.
  • the present invention provides forty-eight genes, twenty-seven of which encode structural genes with the remainder encoding a variety of functions.
  • the present invention is drawn to the following genes or nucleic acids: calC (SEQ ID No. 1), calH (SEQ ID No. 3), calG (SEQ ID No. 5), calA (SEQ ID No. 7), calB (SEQ JD No. 9), calD (SEQ ID No. 11, calF (SEQ TD No. 13), call (SEQ ID No. 15), calJ (SEQ ID No. 17), calK (SEQ ID No. 19), calL (SEQ ID No. 21), calM (SEQ ID No. 23), calN (SEQ ID No.
  • the invention is also drawn to the following proteins or putative proteins: CalC (SEQ DD No. 2), CalH (SEQ TD No. 4), CalG (SEQ TD No. 6), CalA (SEQ TD No. 8), CalB (SEQ ID No. 10), CalD (SEQ TD No. 12), CalF (SEQ TD No. 14), Call (SEQ TD No. 16), CalJ (SEQ ID No. 18), CalK (SEQ TD No. 20), CalL (SEQ TD No. 22), CalM (SEQ TD No.
  • Orf3 SEQ JD No. 60:, Orf4 SEQ JD No. 62), Orf5 (SEQ TD No. 64), Orf6 (SEQ ID No. 66), Orf7 (SEQ TD No. 68), Orf8 (SEQ TD No. 70), Orfl (SEQ TD No. 72), Orfll (SEQ TD No. 74), Orfffl (SEQ TD No. 76), OrflV (SEQ ID No. 78), OrfV (SEQ TD No. 80), OrfVI (SEQ ID No. 82), OrfN ⁇ (SEQ ID No. 84), OrfNm (SEQ TD No. 86), OrflX (SEQ ID No. 88), OrfX (SEQ TD No. 90), OrfXI (SEQ TD No. 92), CalE (SEQ ID No, 95).
  • the present invention is directed to an isolated nucleotide molecule, wherein the nucleotide molecule hybridizes with at least one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 or 94, or a functional derivative of the isolated nucleotide molecule which hybridizes with at least one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 87
  • the isolated nucleotide molecule has the nucleotide sequence of at least one of SEQ TD NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 or 94, i.e., 100% complementarity (sequence identity) with at least one of SEQ TD NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93
  • the isolated nucleotide molecule has at least 90% complementarity (sequence identity) with at least one of SEQ TD NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39,
  • the isolated nucleotide molecule has at least 80% complementarity (sequence identity) with at least one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 or 94.
  • the isolated nucleotide molecule has at least 70% complementarity (sequence identity) with at least one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 or 94.
  • the isolated nucleotide molecule has at least 60% complementarity (sequence identity) with at least one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 or 94.
  • the isolated nucleotide molecule is substantially complementary to at least one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 or 94.
  • an isolated protein encoded by a DNA molecule as described herein above, or a functional derivative thereof.
  • a preferred protein has the amino acid sequence of at least one of SEQ TD NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40,
  • the present invention provides an isolated nucleic acid molecule from Micromonospora echinospora comprising a nonchromoprotein enediyne biosynthetic gene cluster, a portion or portions of said gene cluster wherein said portion or portions encode a protein, a portion or portions of said gene cluster wherein said portion or portions encode a biologically active fragment of a protein, a single-stranded nucleic acid molecule derived from said gene cluster, or a single- stranded nucleic acid molecule derived from a portion or portions of said gene cluster.
  • the present invention provides an isolated nucleic acid molecule from Micromonospora echinospora spp.
  • the present invention also relates to nucleic acids capable of hybridizing with one or more isolated nucleic acids from a nonchromoprotein enediyne biosynthetic gene cluster from Micromonospora echinospora spp. calichensis.
  • the invention provides an expression vector comprising an isolated nucleic acid molecule from a nonchromoprotein enediyne biosynthetic gene cluster from Micromonospora echinospora.
  • the invention provides a cosmid comprising an isolated nucleic acid molecule from a nonchromoprotein enediyne biosynthetic gene cluster from Micromonospora echinospora.
  • the invention provides the isolated nucleic acid molecules of SEQ JD Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 and 94.
  • the present invention provides a host cell transformed with an isolated nucleic acid molecule from a nonchromoprotein enediyne biosynthetic gene cluster from Micromonospora echinospora.
  • Host cells can optionally be of bacterial, yeast, fungal, insect, plant or mammalian origin and can be transformed according to standard methods.
  • the host cell is the bacterium E. coli, Streptomyces spp., or Micromonospora spp.
  • the host cell is the bacterium from the genus Streptomyces or from the genus Micromonospora.
  • the invention is directed to a host cell transformed with an expression vector comprising at least one of the nucleotide sequences of SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 , or 94 or a portion of portions thereof or an allele or alleles thereof.
  • the host cells produce a biologically functional protein or portion of a protein, which protein or portion thereof is encoded by the expression vector.
  • the invention is directed to a host cell transformed with an expression vector comprising calC, or a portion(s) or allele(s) thereof, operably linked to regulatory sequences that enable expression of CalC.
  • the invention provides a host cell transformed with an expression vector comprising calH, or a portion(s) or allele(s) thereof, operably linked to regulatory sequences that enable expression of CalH.
  • the invention provides a host cell transformed with an expression vector comprising calQ, or a portion(s) or allele(s) thereof, operably linked to regulatory sequences that enable expression of CalQ.
  • the invention provides a host cell transformed with an expression vector comprising calG, or a portion(s) or allele(s) thereof, operably linked to regulatory sequences that enable expression of CalG.
  • the invention is directed to a host cell transformed with an expression vector encoding at least one polypeptide comprising the amino acid sequence of SEQ JD Nos. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, or 95 or a functional variant of one or more of those polypeptides.
  • the host cells produce a biologically functional protein or portion of a protein, which protein or portion thereof is encoded by the expression vector.
  • the invention is directed to a host cell transformed with an expression vector encoding CalC, or a functional derivative thereof, operably linked to regulatory sequences that enable expression the encoded polypeptide.
  • the invention provides a host cell transformed with an expression vector encoding CalH, or a functional derivative thereof, operably linked to regulatory sequences that enable expression of the encoded polypeptide.
  • the invention provides a host cell transformed with an expression vector encoding CalQ, or a functional derivative thereof, operably linked to regulatory sequences that enable expression of the encoded polypeptide.
  • the invention provides a host cell transformed with an expression vector encoding the CalG, or a functional derivative thereof, operably linked to regulatory sequences that enable expression of the encoded polypeptide.
  • the invention further provides a method of expressing a protein by culturing a host cell transformed with an expression vector of the present invention, and incubating the host cell for a time and under conditions allowing for protein expression.
  • the invention provides a method of purifying calicheamicin using affinity chromatography.
  • a sample containing calicheamicin is contacted with an affinity matrix having the protein CalC bound thereto, for a time and under conditions allowing calicheamicin to bind to the matrix, eluting calicheamicin from the matrix, and recovering calicheamicin.
  • the present invention provides polypeptides comprising the amino acid sequences of SEQ ID Nos.
  • the invention further provides a method of conferring calicheamicin resistance to a subject comprising obtaining cells from the subject, transforming the cells with the calicheamicin self-resistance gene, and returning the cells to the subject.
  • the calicheamicin self-resistance gene can be targeted and delivered to the desired host cells through known gene therapy delivery systems.
  • the invention further provides a method of producing calicheamicin analogs by altering calicheamicin or its bioactive metabolites through the modulation of the expression of calD, E, F, G, H, J K, N, O, P, Q, S, T, U. V. W. X, 6MSAS, actl-III, orfl, orflll, orfV, and orfVII.
  • modulation can be achieved through selective "knock out", as well as heterologous expression of these genes and their products. Narious combinations of these either mutated or wild type gene products may be used in either in vitro or in vivo calicheamicin analog production.
  • the invention further provides a method for increasing the production of calicheamicin through the introduction of multiple copies of positive regulators and transporters and or by eliminating or reducing the expression of negative regulators (e.g., CalA, B, I, L, OrfS). Additionally, upregulation of calicheamicin resistance genes calC, calN and orfX can be used to decrease the toxicity of calicheamicin to healthy tissues and cells during therapy.
  • negative regulators e.g., CalA, B, I, L, OrfS.
  • the invention provides for a method of transposon mediated mutagenesis or moving chromosomal D ⁇ A fragments in vivo through expression of the or ⁇ integrase and the IS insertional element.
  • biosynthetic genes can ultimately result in increased yields of the gene product by cloning and expressing the biosynthetic gene encoding the rate-limiting enzyme back into the producing organism.
  • biosynthetic genes into strains that make related compounds. Such genes could endow the host organism with the ability to carry out new reactions on the enediyne nucleus, and thus produce novel drugs.
  • the present invention thus also provides means for biosynthetic modification of bioactive secondary metabolites through enediyne combinatorial biosynthesis.
  • biosynthetic modification of bioactive secondary metabolites through enediyne combinatorial biosynthesis.
  • genetic manipulation of the sugar appendage on the metabolites offers avenues for creating potential new drugs.
  • the emerging field of combinatorial biosynthesis has become a rich new source for modified non-natural sugar scaffolds.
  • the present invention addresses this need.
  • the present invention utilizes the fact that glycosyltransferases, which are responsible for the final glycosylation of certain secondary metabolites, show a high degree of promiscuity toward the nucleotide sugar donor. Zhao, L., et al, J. Am. Chem. Soc 1988, 120, 12159-12160.
  • This unselectivity of the glycosyltransferases has the potential for allowing modification of the crucial glycosylation pattern of natural, or non-natural, secondary metabolite scaffolds in a combinatorial fashion.
  • the present invention discloses a method using the recruitment and collaborative action of sugar genes from a variety of biosynthetic pathways to construct composite gene clusters, which make and attach non-natural sugars.
  • the calicheamicin self-resistance mechanisms elucidated utilizing the present invention provide gene therapy approaches, for example, via introduction of enediynes resistance genes into bone marrow cells, thereby increasing resistance and allowing tolerance to chemotherapeutic doses of calicheamicin. Banerjee, D., et al., Stem Cells, 12, 378- 385 (1994).
  • the present invention addresses this need as it provides for the isolation and characterization of a resistance gene and its associated protein for any nonchromoprotein enediynes.
  • Figure 1 depicts the summary of the cosmid clones isolated from M. echinospora genomic library. This figure illustrates the results of the screening of the genomic library for clones carrying the calicheamicin biosynthetic cluster.
  • Figure 2 shows a restriction map of a portion of cosmid clones 4b, 13 a, and 56 and the corresponding location of cal genes from M. echinospora.
  • Figure 3 is a table of the open reading frames ("orfs") in the calicheamicin biosynthetic cluster. This table lists the polypeptides that the genes encode for as well as their proposed or actual determined function in the biosynthetic pathway. a Assignments based upon BLAST search at the amino acid level unless otherwise noted. b Highest probability score obtained, assignment based on biochemical studies. d Only a portion of the orf has been elucidated.
  • Figure 4 is a graph of the UN-visible absorption spectra of purified mbp-CalC.
  • the purified mpb-CalC was analyzed in the following solution: 52 ⁇ M mpb-CalC; 10 mM Tris-HCl, pH 7.5).
  • the inset shows the results of low temperature (4.3 K) the X-band EPR analysis of CalC.
  • 250 ⁇ M mpb-CalC containing 0.5 mol Fe per mol CalC was analyzed in 10 mM Tris-HCl, pH 7.5.
  • Figure 4(b) provides the results of the mbp-CalC in vitro assay.
  • Figure 5 depicts the postulated routes for the biosynthesis of required nucleotide sugars.
  • Figure 6 illustrates a schematic representation of the in vivo production of pikromycin methymycin-calicheamicin hybrid metabolites.
  • Figure 7 depicts the Streptomyces Venezuela methymycin/pikromycin gene cluster. Eight open reading frames (desl-desVTT ⁇ ) in this cluster have been assigned as genes involved in desosamine biosynthesis. This figure also depicts the hybrid pathway toward new methymycin/pikromycin derivatives (11 and 12) produced after heterologous expression of the cal ⁇ gene of calicheamicin in a S. Venezuela mutant.
  • Figure 8 illustrates calicheamicin's (6) four unique sugars which are crucial to tight DNA binding.
  • Sugar (9) is derived from 4-amino-4,6-dideoxyglucose (8) and is part of the restricted N-O connection between sugars A and B.
  • Compound 8 is derived from the corresponding 4-ketosugar (7) via a transamination reaction.
  • the gene calR encodes the desired C-4 aminotransferase allowing conversion of compound (7) to compound (8).
  • Figure 9 is a map illustrating the relative loci of the 48 identified genes spanning approximately 65KB of continuous sequence. Eight of the genes identified show no homologs in the public databases.
  • Figure 10 depicts additional postulated routes for the biosynthesis of required nucleotide sugars.
  • Figure 11 is a schematic showing the iodination of orsellenic acid mediated by CalN and CalT, as well as the subsequent steps of oxidation, mediated by CalS and CalW and methylation, mediated by CalD and CalJ. Additionally, the figure shows the synthesis of putative substrates for the reaction.
  • Figure 12 describes the mechanism of calicheamicin resistance in Micromonospora.
  • calC confers calicheamicin resistance to bacteria.
  • Figure 13 A schematic diagram of the first continuous assay for enediyne- induced D ⁇ A cleavage, the Molecular Break Lights.
  • the solid lines represent covalent bonds
  • dashed lines represent hydrogen bonding
  • letters represent arbitrary bases
  • the gray shaded ball represents the fluorophore (FAM: fluorescein)
  • the black ball represents the corresponding quencher (DABCYL:4-(4- 'demethylaminophenylazo)-benzoic acid)
  • the dashed wedges represent fluorescence.
  • molecular beacons operate by a separation of the fluorophore-quencher pair resulting in a conesponding fluorescent signal.
  • Molecular break lights operate through cleavage of the stem by an enzymatic or non-enzymatic nuclease activity resulting in the separation of the fluorophore-quencher pair and corresponding fluorescent signal.
  • Molecular break lights contain either a preferred calicheamicin recognition site (boldfaced, TCCT) or the BamHI recognition site (bold-faced, GGATCC). The predicted cleavage sites are illustrated by anows.
  • Figure 14 shows the demonstration of molecular break light specificity and general proof of principle. The observed change in fluorescence intensity over time of an assay containing 3.2 nM break light at 37 °C.
  • Break light calicheamicin MLB break light A
  • BamHIMLTi break light B
  • U BamHI U BamHI
  • O n ⁇ BamHI M without enzyme
  • calicheamicin MLB break light A
  • 10 U DNasel Q
  • BamHIMLB break light B
  • 10 U DNasel o
  • calicheamicin MLB break light A
  • Figure 15 shows the cleavage of calicheamicin MLB (break light A) by calicheamicin and esperamicin.
  • Calicheamicin concentrations 31.7 nM (o), 15.9 nM ( ⁇ ), 3.2 nM (0), 1.6 nM ( ⁇ ), 0.78 nM (•) and 0.31 nM ( ⁇ ).
  • Bleomycin concentrations 200 nM (o), 100 nM ( ), 50 nM (0), 25 nM ( ⁇ ) , 12.5 nM ( • ) , 5 nM ( ⁇ ) and 2.5 nM ( ⁇ *• ) .
  • Fe(H) concentrations 50 nM (o) , 125 nM ( ⁇ ) , 250 nM (0) , 500 nM ( ⁇ ) , 1 ⁇ M ( • ) and 2 ⁇ M ( ⁇ ) .
  • Fe(II) concentrations 12.5 ⁇ M (o) , 6.3 M ( ⁇ ) , 3.1 uM (0) , and l.3 ⁇ M ( ⁇ ) .
  • Figure 17 shows the direct in vitro inhibition of calicheamicin-mediated DNA cleavage using the break light assay.
  • 3.6pM break light A is coincubated with 3.5nM calicheamicin with increasing amounts of CalC.
  • Complete inhibition of calicheamicin is achieved with roughly 2-fold excess of CalC.
  • CalC has no effect on esperamicin- induced cleavage of DNA.
  • FIG 18 shows the interaction between CalC and "activated" calicheamicin as measured by an increase in tryptophan fluorescence of CalC.
  • CalC has 5 tryptophan and no cysteine residues and is unaffected by the reductive activator dithiothreitol (DTT).
  • DTT reductive activator dithiothreitol
  • the present invention is directed to the isolation and characterization of the calicheamicin biosynthetic cluster.
  • This cluster encodes the genes that encode the proteins and enzymes that are involved in deoxysugar synthesis (the aryltetrasaccharide), polyketide biosynthesis (the aglycone and aromatic residue of the aryltetrasaccharide) of calicheamicin synthesis, regulation, transport, cluster mobility and calicheamicin resistance.
  • aryltetrasaccharide the aryltetrasaccharide
  • polyketide biosynthesis the aglycone and aromatic residue of the aryltetrasaccharide
  • genes that encode for the aryltetrasaccharide moiety (20,928 bp; D, E, F, G, H, J K, N, O, Q, S, T, U_ X, W, 6MSAS), 12 putative genes which encode for the aglycone (13,284 bp; P, S, V, W, Actl, Actll, Actlll, Orfl, Orflll, OrfV, OrfVI, OrfVII), 13 putative genes involved in membrane transport, regulation, DNA movement and/or resistance (19,704 bp; A, B, Q I, L, M, R, or ⁇ , or ⁇ , OrfVIII, OrflX, OrfX, OrfXI, IS-element), and the remaining 8 genes of unknown function (7383 bp; orfl, or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , Orfll, OrflV).
  • the calicheamicin biosynthetic gene cluster comprises the following genes: calA, ca B, calC, calD, calE, calF, calG, calR, call, call, calK, calL, calM, calN, calO, calP, calQ, calR, calS, call, cal ⁇ , caN, calW, calX, 6MSAS, Actl, Actll, Actlll, or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , or ⁇ , orfl, orfll orflll, orflV orfV, orfVI, orfVII, orfVIII, orflX, orfX, orfXI and an IS-element gene.
  • orfl -8 may contain DNA derived in whole or in part from recombinant vectors LP46 and/or LP54.
  • the above listed genes encode the following polypeptides: CalA (328 amino acids), CalB (561 amino acids), CalC (181 amino acids), CalD (263 amino acids), CalE (420 amino acids), CalF (245 amino acids), CalG (990 amino acids), CalH (338 amino acids), Call (568 amino acids), CalJ (332 amino acids), CalK (440 amino acids), Cal L (562 amino acids), Cal M (416 amino acids), CalN (398 amino acids), CalO (331 amino acids), Cal P (approximately 179 amino acids), CalQ (453 amino acids), CalR (265 amino acids), CalS (1113 amino acids), CalT (280 amino acids), CalU (377 amino acids), CalN (125 amino acids), CalW (449 amino acids), CalX (197 amino acids), 6MSAS (198 amino acids), Actl (207 amino acids), Acffl (136 amino acids), Actin (308 amino acids), Or
  • the inventors began with a genomic library containing the genome of Micromonospora echinospora spp. calichensis.
  • the cosmid library was generated by isolating chromosomal D ⁇ A of Micromonospora echinospora spp. calichensis, fragmenting that chromosomal DNA, inserting the DNA into a cosmid vector and generating a cosmid library according to methods well known in the art. This procedure can be performed using any species of Micromonospora, Streptomyces, or other suitable bacteria.
  • PKS polyketide synthase
  • the cluster encoding for calicheamicin biosynthesis in addition to carrying a PKS-encoding region, would carry both a common glucose-1-phosphate nucleotidyltransferase and a NDP- ⁇ -D-glucose 4,6- dehydratase gene, encoding the putative enzymes E pl , and E 0d , respectively. See figure 5. These enzymes are necessary to convert a sugar (12)(figure 5) to the hypothesized common intermediate, 4-keto-6-deoxy TDP-D-glucose (30). Analogs to 4,6-dehydratases have been previously characterized from E. coli, Salmonella, and Streptomyces.
  • nucleotide transferase from Salmonella has been characterized as an alpha-D-glucose-1 -phosphate thymidylyltransferase.
  • the secondary screen was performed using a probe based upon the postulation that the M. echinospora 's calicheamicin synthesis would begin from a similar precursor found in E. coli, Streptomyces and Salmonella, and that this precursor required a dehydratase to convert it into the common intermediate, 4-keto-6-deoxy TDP-D-glucose (30).
  • a DNA probe (designated E od 1 ) was designed from the conserved NAD + - binding site of bacterial NDP- ⁇ -D-glucose 4,6-dehydratases. He, X., et al., Biochem., 35, 4721-4731 (1996). Southern hybridization of the genomic M. echinospora cosmid library with the E ⁇ 1 probe revealed cross-hybridization with clones 4b, 10a, 13a, 56, and 60. Two additional clones, designated 58 and 66, were also identified in this screen. See Figure 1. This secondary hybridization indicated the clustering of genes encoding both polyketide and deoxysugar biosynthesis.
  • clones 4b, 10a, 13a, 56, and 60 carried PKS I and ⁇ homologues and deoxy sugar biosynthetic genes, as well as encoded the gene responsible for conferring calicheamicin-self resistance.
  • the clones positive for PKS I and ⁇ and deoxy sugar biosynthesis homology and calicheamicin resistance were used to map the biosynthetic cluster.
  • Southern hybridization established similarity between clones 3a, 4a, 4b, 10a, 13a, 16a and 56. In addition, nucleotide sequence overlaps were found between clones 4b, 13a, and 56. See Figure 1. Restriction mapping and Southern hybridization of these clones indicated that the positive cosmid clones conesponded to a continuous region of the M. echinospora chromosome spanning > 100 kb.
  • the present invention thus provides for cosmids having a nucleic acid molecule from Micromonospora echinospora encoding for a nonchromoprotein enediyne biosynthetic cluster.
  • One aspect of the invention relates to transformation of a host cell with M. echinospora DNA.
  • This method provides a reproducible transformation efficiency of ⁇ 10 kanamycin resistant transformants/ g DNA using a pKC 1139-based vector.
  • the host cell can be but is not limited to bacteria, yeast, fungus, insect, plant or mammalian. Transformations of bacteria, yeast, fungus, insect, plant or mammalian cells are performed by methods known in the art.
  • the present invention also provides the isolation and characterization of genes encoding polypeptides involved in calicheamicin resistance such as orfXI and calC .
  • One aspect of the invention relates to an isolated DNA strand having the gene calC and having the DNA sequence SEQ. ID No.: 1.
  • the present invention also relates to an isolated protein CalC, having the amino acid sequence, SEQ TD. NO. 2.
  • the invention further provides for calC gene fragments coding for a bioactive CalC polypeptide.
  • the polypeptide, CalC confers calicheamicin resistance and has 181 amino acids.
  • the invention also provides for CalC fragments conferring calicheamicin resistance.
  • the calC locus was isolated by identifying calicheamicin genomic cosmid clones that were able to grow on luria bertani ("LB") agar plates containing ampicillin and calicheamicin.
  • the DNA of the positive clones (clones that grew on the plates containing calicheamicin) was isolated and subsequent restriction mapping localized the desired phenotype (calicheamicin resistance).
  • the DNA was then sequenced and the open reading frames analyzed to ascertain the orf encoding for the desired phenotype. In vitro studies were also performed and confirmed the ability of CalC to inhibit DNA cleavage.
  • DNA containing calC was cloned into an inducible vector, using known methods, resulting in overexpression of calC.
  • the polypeptide product (CalC) was then isolated and purified to homogeneity. Analysis of the purified CalC revealed that it is a non-heme iron metalloprotein that functions via inhibition of calicheamicin- induced DNA cleavage in vitro.
  • Another aspect of the invention is an expression vector containing calC or a fragment oicalC encoding for a bioactive molecule.
  • a transformed host cell preferably bacteria, more preferably E. coli, containing calC or a fragment of calC encoding for a bioactive molecule.
  • Such transgenic expression of calC results in an 10 5 -fold increase in calicheamicin resistance in E.coli, a 100-fold increase in resistance in S.lividans, and a 50-fold increase in resistance in yeast.
  • the present invention provides for the transformation of human cells with the calC gene.
  • the transgenic expression o ⁇ calC in the HT1080 (human) cell line increased its resistance to calicheamicin 10-fold.
  • This technique allows bone marrow cells, for example, to be removed from a patient being treated with calicheamicin, and for these cells to be transformed with calC, and for the transformed cells to be returned to the patient.
  • This allows the patient to tolerate treatment with calicheamicin or allows the patient to receive higher doses of calicheamicin as the returned human-c ⁇ /C-transformed cells have calicheamicin resistance.
  • the transformation is performed by methods known in the art.
  • the embodiment of the invention would be applicable to many diseases being treated with calicheamicin.
  • the invention further provides for a method of assaying the calicheamicin- induced DNA cleavage and its CalC-mediated inhibition using the molecular break light assay.
  • Two molecular break lights (MLBs) for the experiments are described in example 7.
  • Break light A is comprised of a 10-base pair stem which contained the known calicheamicin recognition sequence 5'-TCCT-3', while break light B carries the BamHI endonuclease recognition sequence 5'-GGATCC-3'.
  • MLBs operate by a separation of the fluorophore-quencher pair resulting a conesponding fluorescent signal.
  • the molecular break lights as illustrated in figure 13, operate through cleavage of the stem by specific enzymatic or non-enzymatic nuclease activity resulting in the separation of the fluorophore- quencher pair and conesponding fluorescent signal (see figure 14). CalC in a two- fold molar excess of calicheamicin, completely abolishes calicheamicin mediated DNA cleavage as monitored by the break light assay (see figure 15).
  • CalC acts as a "cleavage sink", h essence the protein is cleaved as an alternative to the desired DNA target.
  • the invention provides the first such demonstrated mechanism for resistance to a cleavage agent and explains why CalC is able to function in all organisms tested so far (i.e. E.coli, S.lividans, yeast, and humans).
  • the invention further provides for the use of the break light assay to determine calicheamicin titers during production of thereof. Furthermore, the molecular break light assay may be used to determine the DNA cleavage activity of calicheamicin analogs generated using the techniques of this invention.
  • Another aspect of the invention relates to an isolated DNA strand containing the calH gene having the DNA sequence SEQ ID. No: 3.
  • the invention also relates to the polypeptide CalH, having amino acid sequence SEQ TD. No. 4.
  • the invention further provides for calH gene fragments coding for a bioactive CalH. CalH is involved in the formation of the aryltetrasaccharide 4,6-dideoxy ⁇ 4-hydroxylamino-D- glucose moiety. CalH catalyzes the conversion of intermediate (30) to intermediate (39) (figure 5).
  • CalH is a TDP-6-deoxy-D-glycerol-L-threo-4-hexulose 4- transaminase, which catalyzes a pyridoxal phosphate ("PLP")-dependent transamination from glutamate to provide 4-amino-6-deoxy TDP-D glucose (intermediate 39)(figure 5).
  • PBP pyridoxal phosphate
  • the invention also provides for CalH fragments that retain bioactivity.
  • CalH closely resembles perosamine synthase, an enzyme which converts compound 30 to compound 39 (See figure 5) en route to the biosynthesis of TDP-perosamine (TDP-4,6-dideoxy-4-amino-D-mannose) inE. coli. Wang, L., et al., Infect. Immunol, 66, 3545-3551 (1998). Thus CalH is believed to be a 4-ketohexose aminotransferase. To confirm the tentative BLAST assigned function, a combinatorial biosynthesis was performed. Specifically the calR gene from calicheamicin was incorporated into a mutant strain of Streptomyces Venezuela.
  • the 4-dehydrase gene (desl) in the methymycin/pikromycin pathway was deleted in this mutant strain.
  • a promoter sequence from the S. Venezuela methymycin/pikromycin cluster was incorporated in the expression vector to drive the expression of foreign genes (the calH of calicheamicin) in S. Venezuela.
  • wild type S Venezuela methymycin/pikromycin pathway is known to produce methymycin, neomethymycin, pikromycin, and narbomycin. See figure 6.
  • Deletion of the desl gene in the mutant strain led to the accumulation of the CalH substrate, TDP-4-keto- 6-deoxyglucose (compound 30, figure 6).
  • CalH is able to directly mediate the synthesis of the product TDP- 4,6-dideoxy-alpha-D-glucose as demonstrated by HPLC isolation of the product and confirmation by high-resolution mass spectrometry.
  • this compound was found to co-elute with chemically synthesized TDP-4-amino-4,6-dideoxy-alpha-D- glucose.
  • one aspect of the present invention further relates to the construction of a composite gene cluster having the ability to make and attach non-natural sugars.
  • the invention further provides an expression vector having a calicheamicin gene operably linked to regulatory sequences to control expression of the calicheamicin protein, and preferably the regulatory sequence is a Streptomyces promoter.
  • the present invention also relates to two newly synthesized sugars, compound (11) and compound (12)(f ⁇ gure 7).
  • Compound 11 has the formula:
  • Compound 12 has the formula:
  • One aspect of the invention relates to an isolated DNA strand containing the calG gene and having the DNA sequence SEQ ID. NO.: 5.
  • Another aspect of the invention is the protein, CalG, having amino acid sequence SEQ JD. No.: 6.
  • calG encodes a 4,6-dehydratase. Dehydratases had been characterized from E. coli, Salmonella and Streptomyces, (Thompson, M. et al, J. Gen. Microbiol, 138, 779-786 (1992); Vara, J.A., et al., J. Biol.
  • Another aspect of the invention is an expression vector containing calG or a fragment of calG encoding for a bioactive molecule.
  • a transformed host cell preferably bacteria, more preferably, E. coli, containing calG or a fragment of calG encoding for a bioactive molecule.
  • CalG is able to directly mediate the synthesis of the product TDP-4- keto-6-deoxy-alpha-D-glucose as demonstrated by an assay where in the product is known to absorb at 320 nm under basic conditions. In addition this compound was found to co-elute with chemically synthesized TDP-4-keto-6-dideoxy-alpha-D- glucose. CalG has been demonstrated to utilize UDP-glucose as a substrate.
  • CalS appears to be a P450- oxidase homolog which performs the oxidation of intermediate 39 to intermediate 42 (figure 5). The oxidation may occur at the nucleotide sugar level or hydroxylamine formation after the sugar has been transfened to the aglycone.
  • an expression vector containing the calS gene or a fragment of calS encoding for a bioactive molecule there is also provided a transformed host cell, preferably bacteria, more preferably E. coli, containing calG or a fragment of calG encoding for a bioactive molecule.
  • CalQ appears to be a UDP-D-glucose-6 dehydrogenase homolog.
  • the CalQ assay is based upon the requirement of this enzyme for two equivalents of
  • NAD+ for activity.
  • an assay based upon the increase in absorbance (as a result of the conversion of NAD+ to NADH upon the conversion of UDP-alpha-D-glucose to UDP-alpha-D-glucuronic acid).
  • the product was also shown to co-elute with commercially available UDP-glucuronic acid and separately confirmed by high resolution mass spectrometry. This enzyme was also shown to utilize TDP-glucose.
  • an expression vector containing the calQ gene or a fragment ofcalQ encoding for a bioactive molecule there is also provided a transformed host cell, preferably bacteria, more preferably E. coli, containing calQ or a fragment of calQ encoding for a bioactive molecule.
  • the present invention allows genetic manipulation of the biosynthetic gene cluster to produce calicheamicin analogs.
  • the present invention provides for producing calicheamicin analogs by constructing deletions or substitutions of the genes involved in biosynthesis of the aryltetrasaccharide.
  • the invention further provides for in vitro glycosylation by altering the glycosylation pattern of calicheamicin (via a glycosyltransferase) to produce additional analogs.
  • the invention also provides for alteration of the calicheamicin aglycone by genetic manipulation of the genes encoding the biosynthesis of the warhead. Genetic manipulation, such as producing deletions or substitutions are performed using methods known in the art.
  • the invention provides for a method of purifying calicheamicin through affinity chromatography. Because of its homology with calicheamicin, CalC functions as a calicheamicin-sequestering ⁇ nding protein. Affinity chromatography is performed using methods known in the art.
  • the invention relates to the expression of the genes located in the biosynthetic gene cluster by using methods known in the art to insert the genes into a suitable expression vector and operably linking the gene to regulatory sequences to control expression of the gene to produce the protein encoded by the inserted gene.
  • the present invention also provides for expression of biologically active proteins by inserting fragments of genes selected from the biosynthetic gene cluster, which encode for biologically active proteins, into a suitable expression vector, using methods known in the art.
  • the genes would be operably linked to regulatory sequences to control their expression.
  • hybridization as used herein is generally used to mean hybridization of nucleic acids at appropriate conditions of stringency as would be readily evident to those skilled in the art depending upon the nature of the probe sequence and target sequences.
  • the hybridization solution contains 6x S.S.C., 0.01 M EDTA, lx Denhardt's solution and 0.5% SDS.
  • Hybridization is carried out at about 68°C for about 3 to 4 hours for fragments of cloned DNA and for about 12 to about 16 hours for total eukaryotic DNA.
  • the temperature of hybridization is reduced to about 12°C below the melting temperature (TM) of the duplex.
  • TM melting temperature
  • the TM is known to be a function of the G-C content and duplex length as well as the ionic strength of the solution.
  • nucleotide sequence or an amino acid sequence exhibits substantial structural or functional equivalence with another nucleotide or amino acid sequence. Any structural or functional differences between sequences having substantial sequence identity or substantial homology will be de minimis; that is, they will not substantially affect the ability of the sequence to function as indicated in the desired application. Differences may be due to. inherent variations in codon usage among different species, for example. Structural differences are considered de minimis if there is a significant amount of sequence overlap or similarity between two or more different sequences or if the different sequences exhibit similar physical characteristics even if the sequences differ in length or structure. Such characteristics include for example, ability to hybridize under defined conditions, or in the case of proteins, immunological crossreactivity, similar enzymatic activity, etc.
  • two nucleotide sequences are "substantially complementary” if the sequences have at least about 40 percent, more preferably, at least about 60 percent and most preferably about 90 percent sequence similarity between them.
  • Two amino acid sequences are "substantially homologous” if they have at least 40%, preferably 70% similarity between the active portions of the polypeptides.
  • hybridizes to a corresponding portion of a DNA or RNA molecule means that the molecule that hybridizes, e.g., oligonucleotide, polynucleotide, or any nucleotide sequence (in sense or antisense orientation) recognizes and hybridizes to a sequence in another nucleic acid molecule that is of approximately the same size and has enough sequence similarity thereto to effect hybridization under appropriate conditions.
  • the size of the "conesponding portion” will allow for some mismatches in hybridization such that the “conesponding portion” may be smaller or larger than the molecule which hybridizes to it, for example 20-30% larger or smaller, preferably no more than about 12-15 % larger or smaller.
  • a functional derivative of a nucleotide sequence is used herein to mean a fragment, variant, homolog, or analog of the nucleotide sequence ofinterest or of the nucleotide sequence encoding the peptide of interest.
  • a functional derivative may include alternative codons for amino acids, or may code for different amino acids which do not substantially change the function of interest of the peptide encoded by the nucleotide.
  • a functional derivative may retain at least a portion of the function of the nucleotide sequence ofinterest or of the nucleotide sequence encoding the peptide ofinterest, which function permits its utility in accordance with the invention.
  • Such function may include the ability to hybridize with at least one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 , or 94; the ability to hybridize with a substantially homologous DNA from another organism which DNA encodes at least one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92 and 95 or a functional derivative thereof, or with an mRNA transcript thereof
  • a “fragment” of the gene or nucleotide sequence refers to any subset of the molecule, e.g., a shorter polynucleotide or oligonucleotide.
  • a “variant” refers to a molecule substantially similar to either the entire gene or a fragment thereof, such as a nucleotide substitution variant having one or more substituted nucleotides, but which maintains the ability to hybridize with the particular gene or to encode mRNA transcript which hybridizes with the native DNA.
  • a “homolog” refers to a fragment or variant sequence from a different genus or species.
  • An “analog” refers to a non- natural molecule substantially similar to or functioning in relation to either the entire molecule, a variant or a fragment thereof.
  • “Functional derivatives” of the proteins as described herein are fragments, variants, analogs, or chemical derivatives of at least one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92 and 95, and which retain at least a portion of the activity of at least one of SEQ TD NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92 and 95 or retain immunological cross reactivity with an
  • a fragment of the protein refers to any subset of the molecule.
  • Variant peptides may be made by direct chemical synthesis, for example, using methods well known in the art.
  • An analog of a protein refers to a non-natural protein substantially similar to either the entire protein or a fragment thereof.
  • a chemical derivative of a protein may contain additional chemical moieties not normally a part of the peptide or peptide fragment. Modifications may be introduced into the a peptide or fragment thereof by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
  • a protein or peptide according to the invention may be produced by culturing a cell transformed with a nucleotide sequence of this invention (in the sense orientation), allowing the cell to synthesize the protein and then isolating the protein, either as a free protein or as a fusion protein, depending on the cloning protocol used, from either the culture medium or from cell extracts.
  • the protein can be produced in a cell-free system. Ranu, et al., Meth. Enzymol., 60:459-484, (1979).
  • thermocycle sequencing was accomplished from pUC- or pBluescript-based subclones (using Ml 3 primers and primer walking) as well as directly from isolated cosmids (via primer walking).
  • Nucleotide sequence data was acquired using two Applied Biosystems automated 310 genetic analyzers and sequences were subsequently assembled using the Applied Biosystems AutoAssemblerTM DNA sequence assembly software. Dear, S., et al., Nucl Acids Res., 14, 3907-3911 (1991); Huang, X., Genomics, 14, 18-25 (1992). Orf assignments were accomplished using a combination of the computational programs MacNectorTM 6.0 and Brujene.
  • MacVector is a commercially available software package which provides the ability to construct a Micromonospora codon bias table (from known Micromonospora sequences) and subsequently use this codon bias table to search for optimal orfs.
  • the shareware program Brujene was specifically designed for streptomycetes and assigns priority to orfs that illustrate a consistency high G/C% in the wobble position.
  • clones conferring calicheamicin resistance were selected by growth of a Micromonospora genomic bifunctional cosmid library on LB plates containing ampicillin (50 ⁇ g ml "1 ) and calicheamicin (0.25 ⁇ g ml "1 ). In this selection, six clones (3a, 4a, 4b, 10a, 13a and 16a) displayed resistance to calicheamicin. Restriction mapping of these clones localized the desired phenotype to a ⁇ 2kb Pstl-Sacl fragment of DNA. ( Figure 2). Maximum tolerated concentrations of calicheamicin on the LB plates was ascertained. The results are as follows:
  • Nucleotide sequence analysis of the Pstl-Sacl fragment suggested that it contained two possible orfs.
  • the proximal 1 kb of this fragment carried the single orf calD while the distal 1 kb presented oxfcalC.
  • Computer translation of calC and subsequent BLAST analysis revealed no homology with known proteins, while the translation of calD to its respective protein, CalD, revealed the presence of three amino acid motifs typically conserved in S-adenosylmethionein-utilizing O- methyltransferases. Therefore, it was hypothesized that calD was not responsible for calicheamicin resistance.
  • calD responsible for calicheamicin resistance
  • a subclone was engineered (pJT1224) to contain an intact calD, but the truncated calC gene. This subclone was not able to confer resistance to calicheamicin.
  • pJT1232 a subclone containing the calC region was constructed (pJT1232). This clone confened calicheamicin resistance, as indicated in the above chart.
  • calC was cloned into a pMAL-C2 vector.
  • pMAL-C2 by itself could not confer calicheamicin resistance. See above chart.
  • Plasmid pRE7 was then induced with isopropyl Beta-D-thiogalactoside ("TPTG”) to overexpress CalC.
  • TPTG isopropyl Beta-D-thiogalactoside
  • Induced pRE7 confened resistance to calicheamicin and produced a maltose-binding protein CalC fusion protein (mbp-CalC). This resulting overexpression of CalC increased calicheamicin resistance 10 2 -fold in vivo. See above chart.
  • the protein mbp-CalC was overexpressed and purified for further analysis.
  • the mbp-CalC was purified from pRE7/E. coli to homogeneity as judged by SDS- PAG ⁇ .
  • An overnight LB culture (containing 50 mg ml "1 ampicillin and 50 ng ml "1 calicheamicin from a fresh pR ⁇ 7/E. coli colony was grown at 37 °C, 250 rpm to an A 6 oo-0.5, induced with 0.5 mM IPTG and growth continued overnight.
  • the 1.2 kb c ⁇ lH gene was amplified by polymerase chain reaction (PCR) from pJSTl 192i ⁇ n7 , which is a subclone containing a 7.0 kb Kpnl fragment of cosmid 13 a.
  • the amplified gene was cloned into the Ec ⁇ XXb ⁇ l site of the expression vector pDHS617.
  • This expression vector contains an apramycin resistance marker.
  • the plasmid pDHS617 was derived from pOJ1446 (Bierman, M. et al., Gene 1992, 116, 43-49). A promoter sequence from the S.
  • Venezuela methymycin/pikromycin cluster was incorporated in the plasmid to drive the expression of foreign genes in S. Venezuela.
  • the resulting plasmid, pLZ-C242 (containing the calR gene insert and the promoter sequence) was introduced by conjugal transfer using E.coli S 17-1 into a previously constructed S. Venezuela mutant, desl. (Borisova, S. et al., Org. Lett. 1999. 1. 133-136).
  • the desl was replaced by the neomycin resistance gene, which confers resistance to kanamycin
  • the PLS-C242-containing S. venezuela- Desl colonies were identified on the basis of their resistance to apramycin antibiotic.
  • DesI/calH-1 was grown in 100 ml of seed medium at 29 °C for 48 hours and then inoculated and grown in five Liters of vegetative medium.
  • the culture was centrifuged to remove cellular debris and mycella.
  • the supernatant was adjusted to pH 9.5 with concentrated KOH, followed by chloroform extraction.
  • the crude products (700 mg) were subjected to flash chromatography on silica gel using a gradient of 1-20% methanol in chloroform.
  • a major product, 10-deoxymethynolide (ca. 400 mg) were obtained.
  • the two macrolides were further purified by HPLC on a C 18 column using an isocratic mobile phase of acetonitrile/H 2 O (1:1). They were later identified as compound (11) and compound (12)(figure 7) by spectral anaylses.
  • the invention further provides for a method of assaying the calicheamicin-induced DNA cleavage and its CalC mediated inhibition using the molecular break liglit assay.
  • Two molecular break lights for the experiments are shown in Fig. 13.
  • Break light A was comprised of a 10-base pair stem which contained the known calicheamicin recognition sequence 5'-TCCT-3', while break light B carried the BamHI endonuclease recognition sequence 5'-GGATCC-3'.
  • the length of break light B also considered the requirement of a 3 base pair overhang required for BamHI recognition and the stem of break light A was adjusted to a comparable length and melting temperature.
  • the loop of both probes consisted of a T 4 loop to ensure non- hybridizing interactions.
  • DABCYL fluorescein
  • absorbance max 485 nm
  • emission max 517 nm
  • DABCYL 4-(4'-dimethylaminophenylazo)benzoic acid
  • 16a,c,d illustrate cleavage of break light A with varying concentrations of either (1) naturally-occurring enediynes including esperamicin, (2), non-enediyne small molecule agents (such as bleomycin (3) methidiumpropyl-Fe-EDTA, (4), and Fe-EDTA, (5)) as well as the restriction endonuclease BamHI) in the presence of excess reductive activator DTT.
  • this assay allows the detection of 1 in the pM range. This sensitivity compares to that of the biochemical induction assay (BIA), the method of choice in detecting DNA-damaging agents.
  • BIOS biochemical induction assay
  • the sensitivity can be significantly enhanced by simply increasing the concentration of the molecular break light in the assay as demonstrated with the iron-dependent agents.
  • the observed maximum fluorescence obtained upon cleavage of 3.2 nM break light A with either 1 or 2 was identical to that observed with DNasel, consistent with complete degradation of the oligonucleotide.
  • incubation of molecular break light A with either DTT or enediyne alone revealed no change in fluorescence.
  • molecular break light B was cleaved by 1 at an identical rate. This supports the view that the specificity of 1 is more dependent upon context and perhaps less so on DNA sequence. It should also be noted that 1 leads to predominately double-stranded cleavage while 2 provides single-stranded nicks and the cunent molecular break light assay can not distinguish these two phenomena.
  • CalC inhibits calicheamicin mediated DNA cleavage. As illustrated in figure 17, CalC directly inhibits of calicheamicin-mediated DNA cleavage in the break light assay. 3.6pM break light A is coincubated with 3.5nM calicheamicin with increasing amounts of CalC (O.Onm, 1.3nm, 2.6nm, 3.9nm, 5.2nm). Complete inhibition of calicheamicin is achieved with roughly 2-fold excess of CalC. CalC has no effect on esperamicin-induced cleavage of DNA (data not shown). All publications, patents and patent applications refened to herein are incorporated in this application by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un groupe de gènes isolés de Micromonospora echinospora codant la biosynthèse de la calichéamicine. Le groupe de gènes biosynthétiques en question contient des gènes qui codent des protéines et des enzymes utilisés dans la biosynthèse de la calichéamicine, y compris l'aryltétrasaccharide et l'aglycone. Le groupe de gènes comprend en outre le gène qui code la protéine conférant une résistance à la calichéamicine. L'invention concerne également des gènes isolés appartenant au groupe de gènes biosynthétiques considérés, et leurs protéines correspondantes. L'invention concerne par ailleurs de l'ADN qui s'hybride avec le groupe de gènes de la calichéamicine, et les gènes isolés de ce groupe. L'invention concerne enfin des vecteurs d'expression renfermant les gènes du groupe de gènes biosynthétiques décrits, y compris leurs variants fonctionnels, et des cellules hôtes conjuguées avec de l'ADN isolé du génome Micromonospora echinospora spp.calichensis.
EP01274067A 2000-11-28 2001-11-28 Codage de genes de micromonospora echinospora pour la biosynthese de la calicheamicine, et autoresistance vis-a-vis de cette substance Withdrawn EP1356026A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US724797 2000-11-28
US09/724,797 US6733998B1 (en) 1998-12-07 2000-11-28 Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
PCT/US2001/044285 WO2002079465A2 (fr) 2000-11-28 2001-11-28 Codage de genes de micromonospora echinospora pour la biosynthese de la calicheamicine, et autoresistance vis-a-vis de cette substance

Publications (1)

Publication Number Publication Date
EP1356026A2 true EP1356026A2 (fr) 2003-10-29

Family

ID=24911949

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01274067A Withdrawn EP1356026A2 (fr) 2000-11-28 2001-11-28 Codage de genes de micromonospora echinospora pour la biosynthese de la calicheamicine, et autoresistance vis-a-vis de cette substance

Country Status (5)

Country Link
EP (1) EP1356026A2 (fr)
JP (1) JP2005506050A (fr)
CN (1) CN1764720A (fr)
CA (1) CA2430684A1 (fr)
WO (1) WO2002079465A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2387401C (fr) 2001-05-21 2004-10-12 Ecopia Biosciences Inc. Compositions, methodes et systemes pour la production d'enediynes
CN103215282B (zh) * 2013-04-09 2016-08-03 中国科学院上海有机化学研究所 越野他汀的生物合成基因簇及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2354030A1 (fr) * 1998-12-07 2000-06-29 Sloan-Kettering Institute For Cancer Research Genes de micromonospora echinospora codant pour la biosynthese de calicheamicine et auto-resistance a cette derniere

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02079465A2 *

Also Published As

Publication number Publication date
JP2005506050A (ja) 2005-03-03
WO2002079465A3 (fr) 2003-09-04
WO2002079465A2 (fr) 2002-10-10
CN1764720A (zh) 2006-04-26
CA2430684A1 (fr) 2002-10-10

Similar Documents

Publication Publication Date Title
Mendes et al. The two-component phoR-phoP system of Streptomyces natalensis: inactivation or deletion of phoP reduces the negative phosphate regulation of pimaricin biosynthesis
Olano et al. A two-plasmid system for the glycosylation of polyketide antibiotics: bioconversion of ε-rhodomycinone to rhodomycin D
EP2271666B1 (fr) Groupe de gènes nrps-pks, sa manipulation et son utilité
JP2000515390A (ja) 新規ポリケチド誘導体およびそれを製造するための組換え方法
US7790411B2 (en) Everninomicin biosynthetic genes
US8709781B2 (en) System and method for the heterologous expression of polyketide synthase gene clusters
CA2332129A1 (fr) Adn codant pour la methymycine et la pikromycine
EP2766389B1 (fr) Grappe de gènes pour la biosynthèse de la grisélimycine et de la méthylgrisélimycine
JP2002537833A (ja) マイトマイシン生合成遺伝子クラスター
US6733998B1 (en) Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
WO2000037608A2 (fr) Genes de $i(micromonospora echinospora) codant pour la biosynthese de calicheamicine et auto-resistance a cette derniere
WO2002079465A2 (fr) Codage de genes de micromonospora echinospora pour la biosynthese de la calicheamicine, et autoresistance vis-a-vis de cette substance
US8207321B2 (en) Method of obtaining idolocarbazoles using biosynthetic rebeccamycin genes
AU2002219877A1 (en) Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto
US7105491B2 (en) Biosynthesis of enediyne compounds by manipulation of C-1027 gene pathway
Yu et al. Functional analysis of type II thioesterase of Streptomyces lydicus AS 4.2501
US7109019B2 (en) Gene cluster for production of the enediyne antitumor antibiotic C-1027
Park et al. BAC cloning and heterologous expression of a giant biosynthetic gene cluster encoding antifungal neotetrafibricin in streptomyces rubrisoli
EP1925668A2 (fr) Gènes jouant un rôle dans la biosynthèse de la thiocoraline et production hétérologue de cette dernière
Shuai Discovery of natural products through heterologous expression of biosynthetic gene clusters in Streptomyces albus
Pageni et al. Characterization of a chalcosyltransferase (gerGTII) in dihydrochalcomycin biosynthesis
KR100903555B1 (ko) 슈도노카디아 오토트로피카의 사이토크롬 p450 하이드록실레이즈 유전자
JP2004089156A (ja) ビセニスタチン合成酵素遺伝子クラスター、ビセニサミン糖転移酵素ポリペプチドおよび当該ポリペプチドをコードする遺伝子
JP2004534502A (ja) 糖部分を変更するための方法
Praseuth et al. APPLIED CELLULAR PHYSIOLOGY AND METABOLIC ENGINEERING

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030630

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20050310

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051202